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ARTICLE
Augmentation of vaccine-induced humoral and
cellular immunity by a physical radiofrequency
adjuvant
Yan Cao1, Xiaoyue Zhu1, Md Nazir Hossen1, Prateek Kakar1, Yiwen Zhao1 & Xinyuan Chen1
Protein/subunit vaccines often require external adjuvants to induce protective immunity.
Due to the safety concern of chemical adjuvants, physical adjuvants were recently explored
to boost vaccination. Physical adjuvants use physical energies rather than chemicals to
stimulate tissue stress and endogenous danger signal release to boost vaccination. Here
we present the safety and potency of non-invasive radiofrequency treatment to boost
intradermal vaccination in murine models. We show non-invasive radiofrequency can
increase protein antigen-induced humoral and cellular immune responses with adjuvant
effects comparable to widely used chemical adjuvants. Radiofrequency adjuvant can also
safely boost pandemic 2009 H1N1 inﬂuenza vaccination with adjuvant effects comparable
to MF59-like AddaVax adjuvant. We ﬁnd radiofrequency adjuvant induces heat shock pro-
tein 70 (HSP70) release and activates MyD88 to mediate the adjuvant effects. Physical
radiofrequency can potentially be a safe and potent adjuvant to augment protein/subunit
vaccine-induced humoral and cellular immune responses.
DOI: 10.1038/s41467-018-06151-y OPEN
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Traditional live-attenuated and inactivated whole-cell vac-cines have good immunogenicity. Yet, live-attenuatedvaccines face risks to cause diseases in immunocompro-
mised populations and inactivated whole-cell vaccines are asso-
ciated with high reactogenicity. Protein/subunit vaccines are
gaining increasing popularity due to improved safety. Yet, pro-
tein/subunit vaccines have low immunogenicity and often require
addition of external adjuvants to induce protective immunity1.
Adjuvants come from the Latin word adjuvare, meaning to help.
Adjuvants potentiate vaccine-induced immune responses and can
be used to enhance vaccine effectiveness, stimulate speciﬁc
immune responses, elicit broad protection, and reduce antigen
amounts and vaccine doses2. Adjuvants are increasingly used
in modern vaccines and are sometimes essential for success
of vaccines.
Adjuvant development in the past mainly relied on empirical
experience and only a few adjuvants have been approved for
human use2,3. Alum adjuvant has been the most widely used
adjuvant in the globe since its ﬁrst empirical use in 1930s4. Alum
adjuvant induces Th2-biased immune responses with major
enhancement on humoral immunity2,4. MF59 is a squalene
emulsion-based adjuvant ﬁrst approved to boost seasonal inﬂu-
enza vaccine efﬁcacy in 19975. MF59 has since been approved in
more than 30 countries with over 100 million MF59-incorporated
inﬂuenza vaccine doses distributed6. MF59 also induces Th2-
biased immune responses7,8. Besides Alum and MF59, several
Adjuvant Systems AS01 (MPL and QS21 in liposome), AS03
(another squalene emulsion-based adjuvant), and AS04 (MPL
adsorbed on Alum) have been approved to boost malaria RTS,S,
2009 H1N1 pandemic inﬂuenza, and human papillomavirus
vaccine efﬁcacy, respectively9,10. Besides approved adjuvants, a
number of experimental adjuvants also exist, like complete and
incomplete Freund’s adjuvants, most of the pathogen-associated
molecular patterns (PAMPs), and cytokines2,11,12. Yet, experi-
mental adjuvants tend to induce signiﬁcant local and/or systemic
adverse reactions that preclude their use in prophylactic vaccines
in humans2.
Due to the safety concern of chemical adjuvants, physical
adjuvants have recently been explored to boost vaccination
without introducing potentially harmful chemicals into the body.
Physical adjuvants use physical energies rather than chemicals to
stimulate tissue stress to enhance vaccine-induced immune
responses. Dr. Matzinger proposed danger model in 1994 to
explain adaptive immunity could be driven by tissue stress, which
led to identiﬁcation of different endogenous danger signals, such
as heat shock proteins (HSPs), uric acid, adenosine triphosphate
(ATP), double-strand DNA13,14. Endogenous danger signals are a
group of molecules that are sequestered from recognition by
innate immune systems under normal conditions and can release
under tissue stress to alert innate immune systems13,14. Endo-
genous danger signals may serve as vaccine adjuvants to boost
vaccine-induced immune responses. In fact, non-PAMP-based
Alum and MF59 adjuvants have been found to induce uric acid
and ATP release, respectively, to at least partially mediate their
adjuvant effects8,15. Considering physical energies can be brieﬂy
applied to induce tissue stress without long-lasting effects, phy-
sical adjuvants are less likely to induce persistent local or systemic
adverse reactions. Physical adjuvants can also conveniently boost
vaccination without modiﬁcation of vaccine manufacturing.
Different lasers have been explored to boost intradermal (ID)
vaccination. Non-invasive green and near-infrared lasers were
found to enhance antigen uptake, maturation, and mobility of
skin antigen-presenting cells to boost ID vaccine-induced
immune responses16–21. Non-ablative fractional laser (NAFL)
was used to generate micro-sterile inﬂammation arrays and
recruit plasmacytoid dendritic cells (pDCs) to boost ID
vaccination22,23. Besides laser, low-frequency ultrasound was
found to activate epidermal Langerhans cells to boost transcuta-
neous immunization24. Adjuvant effects of near-infrared laser
were found to be comparable or slightly better than Alum adju-
vant in boosting inﬂuenza vaccination16,19. NAFL can be com-
bined with topical Imiquimod (IMIQ) adjuvant to signiﬁcantly
boost inﬂuenza vaccination with NAFL/IMIQ adjuvant effects
comparable to MF59-like AddaVax adjuvant22. Although most of
the physical adjuvants reported to date still remain in the pre-
clinical stages, the safety and potency of physical adjuvants
prompted us to explore whether other types of physical energies
could induce similar or better adjuvant effects by stimulation of
different types of tissue stress and innate immune responses.
Radiofrequencies (RFs) are alternating electromagnetic waves.
RFs at medium-high frequencies (0.3-10MHz) generate tissue
heating with broad applications in Aesthetics (e.g., skin tighten-
ing) and Medicine (e.g., tumor ablation)25,26. This study explores
cosmetic RF treatment of a small area of the skin (2 × 2 cm2)
followed by ID delivery of protein/subunit vaccines into RF-
treated skin to induce tissue stress and boost ID vaccine-induced
immune responses in murine models. We ﬁnd non-invasive RF
treatment induces local inﬂammation, enhances antigen uptake
and maturation of dendritic cells (DCs) in the skin and draining
lymph nodes (dLNs), and signiﬁcantly augments ID ovalbumin
(OVA) and recombinant hemagglutinin (rHA)-induced humoral
and cellular immune responses with RF adjuvant (RFA) effects
non-inferior to widely used chemical adjuvants. RFA can also
safely boost pandemic 2009 H1N1 inﬂuenza (pdm09) vaccination
with adjuvant effects comparable or superior to MF59-like
AddaVax adjuvant based on vaccine doses. RFA is further
found to stimulate heat shock protein 70 (HSP70) release and
activate myeloid differentiation primary response 88 (MyD88) to
mediate its adjuvant effects.
Results
Non-invasive RF induces low-level local inﬂammation. A cos-
metic fractional bipolar RF device equipped with an electrode
array for delivery of RF energies into the skin was used to evaluate
its potential adjuvant effects in the absence of tissue damage. Our
pilot studies found RF treatment of murine dorsal skin at high-
energy setting for more than 2 min could induce instant skin
damage, while no skin damage could be found if treatment was
1.5 min or less. At the end of 1.5 min of RF treatment, skin turned
white with clear signs of electrode array positioning on the skin
surface (Supplementary Fig. 1a). Skin then gradually returned to
its normal color and morphology within 20min (Supplementary
Fig. 1a). Skin histological analysis found 1.5 min of RF treatment
induced immune cell recruitment 2 h after treatment (upper
panels, Supplementary Fig. 1b). RF also increased dermal collagen
levels 24 h after treatment (lower panels, Supplementary Fig. 1b),
indicative of induction of thermal stress and neo-collagen
synthesis, in line with function of the cosmetic RF device. Due
to the induction of signiﬁcant tissue stress without tissue damage,
RF treatment at high-energy setting for 1.5 min was selected for
further evaluation of its impacts on innate and adaptive immunity
in the following studies.
RF-induced local inﬂammation, such as cytokine/chemokine
release and immune cell recruitment, was explored and compared
with that induced by widely used chemical adjuvants, such as
Alum, MPL, and AddaVax. As shown in Fig. 1a, RF induced
relatively low levels of cytokine gene expression except IL6 as
compared with chemical adjuvants (Fig. 1a). IL6 expression was
signiﬁcantly induced by RF, Alum, and AddaVax, and more
signiﬁcantly induced by MPL (Fig. 1a). RF also induced relatively
low levels of chemokine gene expression as compared to chemical
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06151-y
2 NATURE COMMUNICATIONS |  (2018) 9:3695 | DOI: 10.1038/s41467-018-06151-y | www.nature.com/naturecommunications
adjuvants (Fig. 1b). RF induced minimal expression of leukocyte
attractant E-selectin and lymphocyte attractant CXCL9 and
CXCL12, slight expression of DC/macrophage attractant Che-
merin and monocyte chemoattractant CCL2, and signiﬁcant
expression of monocyte chemoattractant CCL7 and monocyte/
eosinophil chemoattractant CCL12 (Fig. 1b). In comparison,
chemical adjuvants induced vigorous expression of CCL2, CCL7,
CCL12, and signiﬁcant expression of E-selectin, Chemerin,
CXCL9, and CXCL12 (Fig. 1b).
RF-induced immune cell recruitment was then explored and
compared with that induced by chemical adjuvants. As shown in
Fig. 1c–f, AddaVax induced the most signiﬁcant recruitment of
innate immune cells (neutrophils, monocytes, macrophages,
eosinophils) that peaked at 24 h. Alum and MPL also induced
signiﬁcant recruitment of innate immune cells and most of the
innate immune cells peaked at 24 or 48 h (Fig. 1c–f). RF induced
signiﬁcant recruitment of innate immune cells that peaked at 6 or
24 h and then returned to baseline levels at 48 h (Fig. 1c–f). Skin
neutrophil, monocyte, and macrophage levels were signiﬁcantly
higher at 48 and 96 h in at least two out of three chemical
adjuvant groups than that in RF group (Fig. 1c–e). These data
indicated that RF treatment induced more transient immune cell
recruitment than chemical adjuvants. Noticeably, skin myeloid
DC (mDC) levels were signiﬁcantly increased after RF, Alum, and
AddaVax treatment, and to a lesser degree after MPL treatment
(Fig. 1g).
RF increases function of speciﬁc DC subsets. DCs play crucial
roles in bridging innate and adaptive immunity. Next we explored
whether RF treatment could improve function of DCs. We ﬁrst
used CD11c as a pan-DC marker and found more DCs took up
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Fig. 1 RF induces low-level local inﬂammation. Dorsal skin of C57BL/6 mice were exposed to RF or intradermally injected with 20 µl Alum (1:1 volume ratio
in PBS), AddaVax (50%, vol/vol in PBS), or MPL (25 µg). Adjuvant-treated and non-treated skins were dissected at indicated times. a, b Heat map of
relative cytokine (a) and chemokine (b) gene expression. Total RNA was extracted followed by reverse transcription and real-time PCR analysis of cytokine
and chemokine gene expression using GAPDH as an internal control. The baseline gene expression level was set at 1. c–g Different innate immune cell
levels in RF and adjuvant-treated skin. Skin was digested in collagenase D and dispase to prepare single-cell suspensions. Cells were then stained with
ﬂuorescence-conjugated antibodies followed by ﬂow cytometry analysis of levels of different cell types: neutrophils (c), monocytes (d), macrophages (e),
eosinophils (f), and mDCs (g) (Supplementary Fig. 2). n= 4. Student’s t-test was used to compare differences between groups at 48 and 96 h. *, p < 0.05;
**, p < 0.01
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ﬂuorescent AF647-OVA following ID injection into RF-treated
skin as compared to sham-treated skin (48% vs. 30%) (Supple-
mentary Fig. 3a, b). In addition, mean ﬂuorescence intensity
(MFI) of AF647 in AF647+ DCs was signiﬁcantly increased in RF
group as compared with that in sham group (12,110 vs. 7712)
(Supplementary Fig. 3c). In dLNs, more AF647+ DCs were found
in RF group than that in sham group (Supplementary Fig. 3d). In
addition, MFI of costimulatory marker CD80 and CD40 in AF647
+ DCs was signiﬁcantly higher in RF group than that in sham
group (Supplementary Fig.3e–g).
Due to the existence of different DC subsets in skin and dLNs,
we further explored whether RF speciﬁcally acted on certain DC
subsets. Skin CD11c+MHC II+ cells can be divided into four
major subsets based on expression of Langerin, CD11b, and
CD103: epidermal and dermal Langerin+CD11b+CD103− cells,
dermal Langerin+CD11b−CD103+, dermal Langerin−CD11b+,
and dermal Langerin−CD11b− cells (Fig. 2a, b)27. We found RF
treatment signiﬁcantly increased antigen uptake in dermal
Langerin+CD11b−CD103+ and dermal Langerin−CD11b− DCs
(Fig. 2c). Antigen uptake in dermal Langerin−CD11b+ DCs was
also increased after RF treatment, but the difference between
RF and sham groups failed to reach a statistically signiﬁcant level
(p= 0.0782, Fig. 2c). Different DC subsets also exist in dLNs,
including classical DCs (cDCs), migratory DCs (migDCs), and
pDCs, which can be differentiated based on the relative
expression of CD11c and major histocompatibility complex
(MHC) II (Fig. 3a)28. RF had no signiﬁcant impact on cDC,
migDC, and pDC levels in dLNs (upper panels, Fig. 3b). Yet, RF
signiﬁcantly increased antigen uptake in all DC subsets (middle
panels, Fig. 3b) and surface expression of CD80 in cDC and pDC
subsets (lower panels, Fig. 3b). Considering cDC can be further
divided into CD11b+ and CD103+ subsets (Fig. 3c) and migDC
can be further divided into Langerin+, Langerin−CD11b−, and
Langerin−CD11b+ subsets (Supplementary Fig. 4a)18,27, we
further explored impacts of RF treatment on individual cDC
and migDC subsets. As shown in Fig. 3d, RF signiﬁcantly
increased percentage of CD11b+ cDC as well as antigen uptake
and surface expression of CD80 in CD11b+ cDC. As for migDCs,
RF signiﬁcantly increased antigen uptake but not cell percentage
or surface expression of CD80 in migDC subsets (Supplementary
Fig. 4b). These results indicated that RF treatment increased
antigen uptake and/or maturation of speciﬁc DC subsets in skin
and dLNs.
RFA augments OVA-induced humoral and cellular immunity.
Model antigen OVA was then used to explore RFA effects. RFA
was further compared with MF59-like AddaVax adjuvant to
boost ID OVA immunization. After prime/boost immunization,
RFA and AddaVax were found to increase anti-OVA antibody
titer by ~ 15- and 24-folds, respectively (Fig. 4a). No signiﬁcant
difference in anti-OVA antibody titer was found between RFA
and AddaVax groups (p > 0.05, Fig. 4a). Induction of OVA-
speciﬁc CD8+ T-cell responses were evaluated by H-2Kb-
restricted OVA257–264 (SIINFEKL) tetramer staining of peripheral
blood mononuclear cells (PBMCs) 1 week after boost. As shown
in Fig. 4b and 4c, RFA more signiﬁcantly increased tetramer+
CD8+ T cells than AddaVax. Mice were further challenged with
E.G7-OVA. We found tumor growth was signiﬁcantly inhibited
in RFA group but not in AddaVax group (Fig. 4d). Tumor
volume on day 22 and 24 was signiﬁcantly smaller in RFA group
than that in AddaVax group (Fig. 4d). All mice succumbed to
tumor within 2 weeks in non-immunized or no adjuvant group,
whereas 20% mice in AddaVax group and 40% mice in RFA
group were tumor-free within the study period (Fig. 4e). These
results indicated that RFA was more potent than AddaVax to
stimulate OVA-speciﬁc CD8+ T-cell responses.
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Fig. 2 RF increases antigen uptake of DCs in skin. Lateral back skin of C57BL/6 mice was exposed to RF or sham treatment followed by ID injection of 2 µg
AF647-OVA into RF or sham-treated skin. ID injection of PBS served as control. Skin was harvested 24 h later and digested in collagenase D and dispase to
prepare single-cell suspensions. Skin cells were then stained with ﬂuorescence-conjugated antibodies followed by ﬂow cytometry analysis. a Live cells were
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RFA was further compared with CpG, a Th1 adjuvant capable
of inducing potent CD8+ T-cell responses29. After prime/boost
immunization, we found RFA and CpG signiﬁcantly increased
anti-OVA antibody titer by ~ 15 and 11 folds, respectively
(Fig. 5a). Antibody subtype analysis found RFA mainly enhanced
IgG1 (Fig. 5b) but not IgG2c antibody titer (Fig. 5c). In
comparison, CpG adjuvant mainly enhanced IgG2c (Fig. 5c)
but not IgG1 antibody titer (Fig. 5b). These results indicated that
RFA and CpG induced Th2- and Th1-biased immune responses,
respectively. We further found combination of RFA and CpG
(RFA/CpG) could induce more potent anti-OVA antibody titer
than either adjuvant alone (Fig. 5a). The ability of RFA to boost
anti-OVA antibody production and the synergistic effects
between RFA and CpG were also observed in BALB/c mice
(Supplementary Fig. 5). Besides humoral immune responses, CD8
+ T-cell responses were evaluated by intracellular cytokine
staining of splenocytes 1 week after boost. As shown in Figs. 5d
and 5e, RFA increased OVA-speciﬁc IL4- and IFNγ-secreting
CD8+ T cells by 129% and 96%, respectively, whereas CpG
increased OVA-speciﬁc IL4- and IFNγ-secreting CD8+ T cells by
81% and 65%, respectively. RFA/CpG more signiﬁcantly
increased IL4-secreting CD8+ T cells by 423% (Fig. 5d). No
signiﬁcant difference could be found in IFNγ-secreting CD8+
T cells among RFA, CpG, and RFA/CpG groups (Fig. 5e). A
second set of mice were similarly immunized and challenged with
E.G7-OVA. As shown in Fig. 5f, tumor growth was signiﬁcantly
inhibited in RFA and CpG groups and more signiﬁcantly
inhibited in RFA/CpG group. All mice succumbed to tumor
within 2 weeks in non-immunized and no adjuvant groups
(Fig. 5g). 20% and 10% mice were tumor-free in RFA and CpG
group, respectively, whereas 50% mice were tumor-free in RFA/
CpG group (Fig. 5g). These results indicated that RFA had similar
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Fig. 4 Comparison of RFA with AddaVax to boost ID OVA-induced humoral and cellular immune responses. C57BL/6 mice were intradermally immunized
with 10 µg OVA alone or in the presence of RFA, or intramuscularly immunized with 10 µg OVA in the presence of AddaVax. Immunization was repeated
2 weeks later. a Serum anti-OVA antibody titer was measured 2 weeks after boost. b, c PBMCs were isolated one week after boost, stimulated with OVA
followed by staining with ﬂuorescence-conjugated anti-CD4, anti-CD8 antibodies, and H-2Kb-restricted OVA257–264 tetramer. Frequency of tetramer+
CD8+ T cells was analyzed by ﬂow cytometry. Cells were ﬁrst gated based on CD4 and CD8 expression and CD8+CD4− cells were further analyzed based
on tetramer staining. Representative dot plots were shown in b and percentage of tetramer+CD8+ T cells were shown in c. d, e Two weeks after boost,
mice were challenged with 5 × 105 E.G7-OVA cells. Tumor growth (d) and percentage of tumor-free mice (e) were monitored for total 60 days. n= 5. One-
way ANOVA with Tukey’s multiple comparison test was used to compare differences between groups in a and c. Two-way ANOVA with Bonferroni post
test was used to compare tumor growth in d. Log-rank test with Bonferroni correction was used to compare differences between adjuvant (RFA or
AddaVax) and no adjuvant groups in e. *p < 0.05; **p < 0.01; ***p < 0.001. NS not signiﬁcant. Representative of two independent experiments
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Fig. 5 Comparison of RFA with CpG to boost ID OVA-induced humoral and cellular immune responses. C57BL/6 mice were intradermally immunized with
10 µg OVA alone or in the presence of RFA, CpG, or RFA/CpG. Immunization was repeated 2 weeks later. a–c Serum anti-OVA IgG (a), and subtype IgG1
(b), and IgG2c antibody titer (c) were measured 2 weeks after boost. d, e Splenocytes were prepared one week after boost, stimulated with OVA followed
by intracellular cytokine staining and ﬂow cytometry analysis. Percentage of IL4 and IFNγ-secreting CD8+ T cells was shown in d and e, respectively.
f, g Another set of mice were similarly immunized as above and then subcutaneously challenged with 106 E.G7-OVA cells 2 weeks after boost. Tumor
volume (f) and percentage of tumor-free mice (g) were monitored for total 100 days. n= 8–9. One-way ANOVA with Tukey’s multiple comparison test
was used to compare differences between groups in a–e. Two-way ANOVA with Bonferroni post-test was used to compare differences in f. Log-rank test
with Bonferroni correction was used to compare differences between adjuvant (RFA, CpG, or RFA/CpG) and no adjuvant groups in g. *p < 0.05; **p < 0.01;
***p < 0.001. NS not signiﬁcant. Representative of two independent experiments
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adjuvant potency to CpG in stimulation of OVA-speciﬁc CD8+
T-cell production.
The ability of RFA to stimulate OVA-speciﬁc CD8+ T-cell
responses was further explored by adoptive transfer of carboxy-
ﬂuorescein succinimidyl ester (CFSE)-stained OT-I T cells to
syngeneic C57BL/6 mice. As shown in Fig. 6a, OVA immunization
alone stimulated low levels of OT-I T-cell proliferation, whereas
incorporation of RFA induced vigorous OT-I T-cell expansion. The
ability of RFA to stimulate OT-I T-cell proliferation was at least
comparable to CpG and AddaVax adjuvants (Fig. 6b). The above
data indicated that RFA possessed potent humoral and cellular
adjuvant effects to boost OVA immunization.
RFA augments rHA-induced humoral and cellular immunity.
rHA of inﬂuenza A/California/07/2009 (H1N1) was then used as
a different protein antigen to explore RFA effects. RFA was fur-
ther compared with AddaVax and Alum to boost rHA immu-
nization considering the same types of adjuvants have been
approved to boost seasonal and/or pre-pandemic inﬂuenza
vaccination6,30. After prime/boost immunization, we found rHA-
speciﬁc IgG antibody titer was signiﬁcantly increased in RFA
group as compared with that in no adjuvant group (Fig. 7a). rHA-
speciﬁc IgG antibody titer in RFA group showed no signiﬁcant
difference when compared with that in AddaVax group, but was
signiﬁcantly higher than that in Alum group (Fig. 7a). rHA-
speciﬁc IgG1 antibody titer showed the same trend to total IgG
antibody titer (Fig. 7b). rHA-speciﬁc IgG2c antibody titer was
signiﬁcantly higher in RFA group than that in AddaVax or Alum
group (Fig. 7c). More signiﬁcant induction of IgG1 as compared
to IgG2c antibody titer indicated that RFA induced Th2-biased
immune responses (Fig. 7b, c). rHA-speciﬁc CD8+ T-cell
responses were then analyzed by intracellular cytokine staining
of PBMCs 1 week after boost. As shown in Figs. 7d and 7e, RFA
signiﬁcantly increased rHA-speciﬁc IFNγ-secreting CD8+ T cells
by ~ 160%, whereas AddaVax and Alum failed to increase IFNγ-
secreting CD8+ T cells. These results indicated that RFA was
comparable to AddaVax to enhance rHA-speciﬁc antibody
responses and more potent than AddaVax to enhance rHA-
speciﬁc CD8+ T-cell responses. Our data also indicated RFA was
more potent than Alum to enhance rHA-speciﬁc humoral and
cellular immune responses.
RFA boosts pdm09 vaccination. Pdm09 vaccine composed of
highly puriﬁed surface antigens was used to further evaluate RFA
effects. Mice were intradermally immunized with 0.3 or 0.06 µg
pdm09 vaccine in the presence or absence of RFA or intramuscu-
larly immunized with the same vaccine dose in the presence of
AddaVax. Serum hemagglutination inhibition (HAI) titer was
measured 3 weeks later. Serum HAI titer was signiﬁcantly increased
from 9 in no adjuvant group to 31 in RFA group and 35 in
AddaVax group (Fig. 8a). No signiﬁcant difference in HAI titer
could be found between RFA and AddaVax groups (Fig. 8a). ID
immunization in the presence of RFA induced minimal local
reactions as evidenced by lack of skin damage or color change
(Supplementary Fig. 6a). Rectal temperature and serum cytokine
levels were measured as indicators of systemic reactions. No sig-
niﬁcant difference in rectal temperature was found in all groups
before immunization (left panel, Supplementary Fig. 6b). Rectal
temperature slightly but signiﬁcantly increased in RFA and Adda-
Vax groups 6 h after immunization despite the lack of a signiﬁcant
difference among no adjuvant, RFA, and AddaVax groups (middle
panel, Supplementary Fig. 6b). Rectal temperature then returned to
baseline levels in RFA and AddaVax groups at 24 h (right panel,
Supplementary Fig. 6b). Serum tumor necrosis factor α (TNFα)
remained at baseline levels in all groups (left panel, Supplementary
Fig. 6c). Serum IL6 slightly increased in all immunization groups
and yet showed no signiﬁcant difference when compared to that in
non-immunized group (right panel, Supplementary Fig. 6c). These
results indicated that RFA had a good local and systemic safety to
boost pdm09 vaccination. After lethal viral challenges, signiﬁcant
protection was only induced in RFA and AddaVax groups (Fig.8b,
c). All mice died in 6 days in non-immunized group and in 10 days
in no adjuvant group, whereas ~ 60% mice survived in RFA and
AddaVax groups (Fig. 8b). Body weight of live mice gradually
recovered to their original levels in RFA and AddaVax groups
(Fig. 8c). Signiﬁcant HAI titer (~ 23) was also induced in RFA
group when vaccine dose was reduced to 0.06 µg, whereas AddaVax
completely lost its adjuvanticity at this vaccine dose (Fig. 8d).
Following lethal viral challenges, signiﬁcant protection was only
observed in RFA group (Fig. 8e). All mice died in 9 days in non-
immunized, no adjuvant, and AddaVax adjuvant groups, while 60%
mice in RFA group survived (Fig.8e). Body weight of live mice in
RFA group gradually recovered to less than 5% below their original
levels (Fig. 8f). Our studies indicated that RFA could signiﬁcantly
boost pdm09 vaccination with adjuvant effects comparable or better
than AddaVax adjuvant depending on vaccine doses.
RFA stimulates HSP70 synthesis and activates MyD88 path-
way. RFA likely induces tissue stress and release of endogenous
danger signals to mediate its adjuvant effects. We ﬁrst explored
whether thermal heating was crucial for RFA effects. As shown in
Supplementary Fig. 7, pre-cooling of local skin and RF tips sig-
niﬁcantly reduced RFA effects. With prior cooling, RFA failed
to signiﬁcantly increase anti-OVA antibody titer after prime
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Fig. 6 RFA stimulates signiﬁcant OT-I T-cell proliferation in vivo. CFSE-stained OT-I T cells were adoptively transferred to syngeneic C57BL/6 mice
followed by ID immunization of 10 µg OVA alone or in the presence of RFA, AddaVax, or CpG adjuvant 24 h later. ID injection of PBS served as control.
DLNs were harvested 4 days later and analyzed for proliferation of OT-I T cells by ﬂow cytometry. Live cells were gated and then plotted based on CD4
and CD8 expression. CD8+CD4− T cells were analyzed for CFSE levels. a Representative dot plots showing percentage of CFSE+ cells in CD8+ T cells.
b Percentage of CFSE+ cells in CD8+ T cells of different groups. n= 8–13. One-way ANOVA with Tukey’s multiple comparison test was used to compare
differences between groups. *p < 0.05; ***p < 0.001. NS, not signiﬁcant. Representative of three independent experiments
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(Supplementary Fig. 7a) and only increased anti-OVA antibody
titer by ﬁvefolds after boost (Supplementary Fig. 7b). Thermal
heating may induce release of heat shock proteins (HSPs) to
mediate vaccine-induced immune responses. HSPs are highly
abundant intracellular proteins with important chaperone func-
tions and can be classiﬁed into about ten families based on
molecular weight and intracellular locations31. HSP70 is among
the mostly explored HSPs with potent vaccine adjuvant effects31.
As HSP70 has two isoforms (inducible HSP70 and constitutive
HSc70)32, we explored impacts of RFA on protein levels of both
isoforms. As shown in Fig. 9a, RFA signiﬁcantly increased HSP70
but not HSc70 levels at 6 and 24 h. To explore whether RFA
effects were speciﬁc to HSP70, we evaluated protein levels of
inducible HSP9033. We found RFA failed to increase HSP90 levels
(Fig. 9a). Increased HSP70 levels were further conﬁrmed by
immunohistochemistry (IHC) analysis. In non-treated skin,
positive HSP70 staining was found in epidermis and speciﬁc
dermal structures, like hair follicles and sebaceous glands
(Fig. 9b). In contrast, more uniform and intense HSP70 staining
was found across entire epidermis and dermis of RFA-treated
skin (Fig. 9b). Considering HSP70 can bind to Toll-like receptor
(TLR) 2 and TLR4 and MyD88 is located downstream of these
TLRs34,35, we explored whether MyD88 was crucial for RFA
effects. As shown in Fig. 9c, lack of MyD88 signiﬁcantly reduced
RFA effects. RFA only increased anti-OVA antibody titer by ~ 2.5
folds in MyD88 knockout (KO) mice, whereas RFA increased
anti-OVA antibody titer by over 25 folds in wild-type (WT) mice
(Fig. 9c). In further support, peptide inhibitor of MyD88 but not
control peptide signiﬁcantly inhibited RFA effects (Fig. 9d).
Serum anti-OVA antibody titer was reduced by more than 70%
by MyD88-speciﬁc peptide and only ~ 10% by control peptide
(Fig. 9d). NALP3 inﬂammasome represents another signaling
pathway that can be activated by a variety of endogenous danger
signals36–38. We found lack of NALP3 had no signiﬁcant impacts
on RFA effects (Supplementary Fig. 8). Our data indicated RFA
stimulated HSP70 synthesis and activated MyD88 to mediate its
adjuvant effects.
Discussion
This study, for the ﬁrst time, proved that non-invasive RF
treatment could signiﬁcantly boost protein/subunit vaccine-
induced humoral and cellular immune responses with RFA
effects non-inferior to widely used chemical adjuvants. RFA sig-
niﬁcantly increased OVA-induced antibody production with
adjuvant effects comparable to AddaVax (Fig. 4a) and CpG
adjuvant (Fig. 5a), and enhanced rHA-induced antibody pro-
duction with adjuvant effects comparable to AddaVax and
superior to Alum adjuvant (Fig. 7a). RFA also signiﬁcantly
increased pdm09 vaccine-induced HAI titer with adjuvant effects
comparable to AddaVax at 0.3 µg vaccine dose (Fig. 8a). RFA also
signiﬁcantly increased pdm09 vaccine-induced HAI titer when
vaccine dose was reduced to 0.06 µg (Fig. 8d). Interestingly,
AddaVax completely lost its adjuvanticity at this low vaccine dose
(Fig. 8d). Consistent with HAI titer, signiﬁcant protection against
lethal viral challenges was observed in RFA and AddaVax groups
at 0.3 µg vaccine dose (Fig. 8b, c) and only in RFA group at
0.06 µg vaccine dose (Fig. 8e, f). Remarkably, a similar survival
rate was observed in RFA group when vaccine dose was reduced
from 0.3 to 0.06 µg (Figs. 8b and 8e), hinting RFA may possess
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Fig. 7 RFA increases rHA-induced humoral and cellular immune responses. C57BL/6 mice were intradermally immunized with 5 µg rHA alone or in the
presence of RFA, or intramuscularly immunized with 5 µg rHA in the presence of AddaVax or Alum. Immunization was repeated 2 weeks later. a–c Serum
rHA-speciﬁc IgG (a), and subtype IgG1 (b) and IgG2c antibody titer (c) measured 2 weeks after boost. d, e PBMCs were isolated 1 week after boost,
stimulated with rHA followed by intracellular cytokine staining and ﬂow cytometry analysis of percentage of IFNγ-secreting CD8+ T cells. Representative
dot plots were shown in d and percentage of IFNγ-secreting CD8+ T cells was shown in e. n= 4–6. One-way ANOVA with Tukey’s multiple comparison
test was used to compare differences between groups. *p < 0.05; **p < 0.01; ***p < 0.001. NS not signiﬁcant. Representative of two independent
experiments
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signiﬁcant dose-sparing effects to boost pdm09 vaccination.
Despite of similar survival rates, high vaccine dose (0.3 µg) in the
presence of RFA has been associated with less maximum body
weight loss (10% vs. 16%) and more complete body weight
recovery (+ 2.4% vs. − 4.5%) as compared with low vaccine dose
(0.06 µg) in the presence of RFA (Fig. 8c–f). These results indi-
cated that the physical RFA was at least comparable to the highly
potent MF59-like AddaVax adjuvant to boost pdm09 vaccination.
Besides humoral adjuvant effects, RFA also possessed potent
cellular adjuvant effects as evidenced by strong induction of
OVA and rHA-speciﬁc CD8+ T-cell responses (Figs. 4c, 5d,
5e, 7e). The ability of RFA to stimulate OVA-speciﬁc CD8+
T cells was also conﬁrmed by adoptive transfer of CFSE-labelled
OT-I T cells to syngeneic mice followed by OVA immunization
in the presence of RFA. We found vigorous expansion of CFSE-
labelled OT-I T cells in RFA group but not in no adjuvant
group (Fig. 6). RFA also showed at least similar potency to
AddaVax and CpG adjuvants to stimulate proliferation of
OVA-speciﬁc OT-I T cells (Fig. 6). Consistent with strong
induction of OVA-speciﬁc CD8+ T-cell responses, OVA
immunization in the presence of RFA but not OVA immuni-
zation alone signiﬁcantly inhibited E.G7-OVA tumor growth
(Figs. 4d, 5f). Protein antigens generally don’t stimulate CD8+
T-cell responses considering they are mainly presented on
MHC class II molecules and stimulate CD4+ T-cell responses39.
It’s intriguing how protein antigens gain access to stimulate
CD8+ T-cell responses following RFA treatment. One expla-
nation is that HSP70 induced after RFA treatment facilitates
cross-presentation of protein antigens on MHC class I mole-
cules for stimulation of CD8+ T-cell responses31. The ability of
RFA to simultaneously boost both arms of adaptive immunity is
promising to improve overall protective efﬁcacy of vaccines due
to the differential roles of humoral and cellular immunity in
prevention and elimination of virus-infected cells. In pdm09
vaccine challenge studies, we observed similar rates of body
weight loss (~ 9%) in the ﬁrst 5 days in RFA and AddaVax
groups (Fig. 8c), in line with similar HAI titers induced in both
groups (Fig. 8a). After 5 days, no further body weight loss was
observed in RFA group, while more body weight loss was
observed in AddaVax group (Fig. 8c). This led to less maximum
body weight loss in RFA group as compared with that in
AddaVax group (9% vs. 13%). Less maximum body weight loss
in RFA group may be due to the induction of vaccine-speciﬁc
CD8+ T-cell responses to eliminate virus-infected cells, which
remains to be explored in the near future.
RFA also has a good safety to boost ID vaccination. RFA
induced transient low-level local inﬂammation, whereas che-
mical adjuvants induced persistent strong local inﬂammation
(Fig. 1). Pdm09 vaccination in the presence of RFA induced
minimal local and systemic reactions (Supplementary Fig. 6).
Despite a slight increase of rectal temperature at 6 h in RFA and
AddaVax groups, rectal temperature returned to baseline levels
at 24 h in both groups (Supplementary Fig. 6). Besides the good
local and systemic safety, the physical RFA introduces no for-
eign materials into the body and is less likely to induce Auto-
immune/Inﬂammatory Syndromes Induced by Adjuvants, a
term recently coined to describe rare clinical conditions (i.e.,
gulf-war syndromes, macrophagic myofasciitis, and narcolepsy)
associated with immunization of chemical adjuvant-containing
vaccines40.
Regarding cellular adjuvantation mechanisms, we found RFA
signiﬁcantly improved antigen uptake and maturation of DCs in
skin and dLNs (Figs.2, 3, Supplementary Fig. 3, 4). In skin, we
found dermal Langerin+CD11b−CD103+ and Langerin−CD11b−
DCs improved antigen uptake following RFA treatment (Fig. 2c).
In dLNs, CD11b+ but not CD103+ cDC improved antigen uptake
and maturation (Fig. 3d) and all migDC subsets improved antigen
uptake but not maturation following RFA treatment (Supple-
mentary Fig. 4b). Although laser adjuvant also improved DC
function16–18, DC subsets that responded to laser treatment dif-
fered from that responded to RF treatment. In one recent study,
near-infrared laser was found to modulate migDC but not cDC or
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Fig. 8 RFA boosts pdm09 vaccination. a–c C57BL/6 mice were intradermally immunized with 0.3 µg pdm09 vaccine alone (no adjuvant) or in the presence
of RFA (RFA), or intramuscularly immunized with the same vaccine dose in the presence of AddaVax (AddaVax), or intradermally injected with the same
volume of PBS (non-immunized). Serum HAI titer was measured 3 weeks later (a). Mice were then intranasally challenged with 10 × LD50 of mouse-
adapted pdm09 viruses. Survival and body weight loss were monitored daily for 14 days and shown in b and c, respectively. d–f C57BL/6 mice were
similarly immunized as above at 0.06 µg vaccine dose. HAI titer was measured 3 weeks later (d). Mice were then challenged with 10 × LD50 of mouse-
adapted pdm09 viruses. Survival and body weight loss were similarly monitored and shown in e and f, respectively. n= 12–14 in a–c and 8–9 in d–f. One-
way ANOVA with Tukey’s multiple comparison test was used to compare differences between groups in a and d. Log-rank test with Bonferroni correction
was used to compare differences between adjuvant (RFA, AddaVax) and no adjuvant groups in b and e. *p < 0.05; **p < 0.01. NS not signiﬁcant.
Representative of two independent experiments
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pDC to mediate its adjuvant effects18. In addition, laser adjuvant
was largely non-inﬂammatory without induction of signiﬁcant
local inﬂammation16–18. These divergences may explain the dif-
ferent adjuvant effects induced by laser and RF16–18.
Regarding tissue stress, we found thermal stress played a crucial
roles in RFA effects as we found pre-cooling of local skin and RF
tips could signiﬁcantly reduce RFA effects especially in primary
immunization (Supplementary Fig. 7). Regarding endogenous
danger signals, we found RFA signiﬁcantly increased HSP70 levels
(Fig. 9a, b). HSP70 is able to bind hydrophobic regions of antigenic
peptides, increase antigen presentation on MHC class I and II
molecules, and enhance CD4+ and CD8+ T-cell responses31. In
addition, only a small amount of peptides (a few hundred picto-
grams) are required to induce potent immune responses when
complexed with HSP7031. The ability of RFA to boost both
humoral and cellular immune responses (Figs. 4, 5, 7) and elicit
signiﬁcant HAI titer at low pdm09 vaccine dose (0.06 µg) (Fig. 8d)
is in line with the above features of HSP70. Furthermore, we found
MyD88 played a crucial role in RFA effects (Fig. 9c, d), which is also
in line with the literature that HSP70 can bind to TLR2 and TLR4
and MyD88 is located downstream of these TLRs31,41. Our study is
also consistent with a recent study, in which a microneedle patch
loaded with tumor lysate and melanin was exposed to near-infrared
light to generate transdermal heat to promote anti-tumor immune
responses42. In that study, heat generation was associated with
increase of HSP70 expression42. That study and our work support
induction of dermal heating and HSP70 release to boost vaccine-
induced immune responses.
With increasing use of protein/subunit vaccines, novel adju-
vants are highly demanded to improve vaccine efﬁcacy and aid in
development of new vaccines. Considering protein/subunit vac-
cines often lack the ability to induce CD8+ T-cell immune
responses, ideal adjuvants better augment both humoral and
cellular immune responses to improve overall protective efﬁcacy
of vaccines. RFA is promising to be one such adjuvant with good
safety and potency to boost both arms of adaptive immunity. RF
also has unique advantages to serve as vaccine adjuvant con-
sidering RF energy can penetrate deep into the tissue (at least a
few millimeters) and RF energy absorption is not affected by skin
color43. RFA can conveniently boost vaccination without pre-
mixing with vaccines and thus requires no modiﬁcation of vac-
cine manufacturing.
Methods
Reagents. OVA (A5503) and MPL (L6895) were purchased from Sigma (St. Louis,
MO). AddaVax, Pepinh-MYD, and Pepinh-Control peptides were purchased from
Invivogen (San Diego, CA). CpG 1826 was synthesized by Trilink Biotechnologies
(San Diego, CA). Alum (Imject) was ordered from Thermo Fisher Scientiﬁc
(Rockford, lL). rHA of Inﬂuenza A/California/07/2009 (H1N1) (FR559) was
obtained from International Reagent Resource (IRR, Manassas, VA). Monovalent
2009 H1N1 inﬂuenza (pdm09) vaccine (NR-20083) was obtained from BEI
Resources (Manassas, VA). Fluorescence-conjugated antibodies used in immu-
nostaining and ﬂow cytometry were purchased from eBiosciences, Biolegends, or
Affymetrix, all from San Diego, CA.
Mice. C57BL/6 and BALB/c mice (6–8 weeks old, male) were purchased from
Charles River Laboratories (Wilmington, MA). MyD88 and NALP3 KO mice and
OT-I transgenic mice were obtained from Jackson Laboratory (Bar Harbor, ME).
Animals were housed in animal facilities of University of Rhode Island (URI) and
anesthetized for hair removal, RF treatment, and immunization. Animal experi-
ments involving inﬂuenza viruses were conducted in animal biosafety level 2
(ABSL2) facility of URI. All animal procedures were approved by the Institutional
Animal Care and Use Committee of URI.
RF device. A cosmetic fractional bipolar RF device of ~ 1MHz (Norlanya
Technology Co., Hong Kong, China) equipped with 12 × 12 array of microelec-
trodes in 2 × 2 cm2 area was used. This device has three energy settings (low,
medium, high) and high-energy setting was used in this study to induce signiﬁcant
tissue stress in 1–2 min. For RF treatment, a thin layer of ultrasound coupling
medium was applied on the skin surface as recommended by manufacturer and RF
device was then ﬁrmly pressed to allow treatment tips to have a close contact with
skin surface.
Immunization. Hair on the lateral dorsal skin of mice was shaved and
completely removed with the help of a hair removal lotion (Nair). Next day, hair-
removed skin was exposed to RF or sham treatment for indicated time (RF was
not activated in sham treatment) followed by ID injection of 10 µg OVA, 5 µg
rHA, 0.3 or 0.06 µg pdm09 vaccine into RF- or sham-treated skin. Endotoxin
levels of OVA was reduced with Detoxi-Gel Endotoxin Removing Column
(20344, Thermo Fisher Scientiﬁc) from original 60 EU/ml to below 15 EU/ml for
in vivo application44. Endotoxin levels were measured by Pierce LAL
Chromogenic Endotoxin Quantiﬁcation Kit (88282, Thermo Fisher Scientiﬁc).
In chemical adjuvant groups, mice were ID injected with the same amount of
antigen in the presence of 30 µg CpG, or intramuscularly injected with the
same amount of antigen in the presence of AddaVax (50%, vol/vol) or Alum
(1:1 volume ratio) except otherwise speciﬁed. Intramuscular delivery of
AddaVax and Alum in most of the experiments was to avoid signiﬁcant local
reactions following ID delivery of the two adjuvants as revealed in our pilot
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Fig. 9 RFA increases HSP70 levels and activates MyD88. a C57BL/6 mice
were exposed to RF and skin HSP70, HSc70, and HSP90 levels were then
analyzed by western blotting at 6 and 24 h (hr) using GAPDH as internal
control. b Representative IHC images of HSP70 expression in RF-treated
and non-treated skin at 24 h. Scale: 250 µm. c WT and MyD88 KO mice
were exposed to RF or sham treatment followed by ID injection of 10 µg
OVA into RF or sham-treated skin. Serum anti-OVA antibody titer was
measured 2 weeks later. n= 4–5. d WT mice were intradermally injected
with 100 µg Pepinh-Control or Pepinh-MyD, or the same volume of PBS 3
and 1 h before RF treatment and ID OVA immunization at 10 µg dose. OVA
immunization alone served as control (No adjuvant). Serum anti-OVA
antibody titer was measured 2 weeks later. n= 4–5. One-way ANOVA with
Tukey’s multiple comparison test was used to compare differences
between groups in c and d. *p < 0.05; **p < 0.01. NS not signiﬁcant.
Representative of two independent experiments in c and d
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studies. For combinatorial adjuvant groups, mice were exposed to RF or sham
treatment followed by ID injection of 10 µg OVA in the presence of 30 µg CpG.
Antibody titer measurement. Serum antibody titer was measured by
enzyme-linked immunosorbent assay (ELISA). In brief, vaccine antigens (1–10 µg/
ml) were coated into 96-well ELISA plates at 4˚C overnight. After blocking with 5%
non-fat milk, 2-serial dilutions of immune sera were added and incubated at
room temperature for 90 min. After washing in phosphate-buffered saline (PBS)
supplemented with 0.05% Tween 20 (PBST), horse-radish peroxidase (HRP)-
conjugated sheep anti-mouse IgG secondary antibodies (1:5000, NA931, GE
Healthcare Life Sciences) were added and incubated at room temperature for 1 h.
After washing in PBST, TMB substrates were added and reactions were then
stopped by addition of 3M H2SO4. Optical absorbance (OD450/490 nm) was
read in a microplate reader (Molecular Device). Serum antibody titer was
deﬁned as the reciprocal dilution factor that resulted in OD450/490 nm that
was ~ 3 times higher than the background values. For detection of subtype anti-
body titer, HRP-conjugated anti-mouse IgG1 and IgG2a or IgG2c secondary
antibodies were used.
Cell-mediated immune response. To measure vaccine-speciﬁc CD4+ and CD8+
T cells in PBMCs, small amount of blood (~ 50 µl) was collected into
heparinized tubes followed by centrifugation at 1,300 rpm for 5 min. After red
blood cell (RBC) lysis, PBMCs then were stimulated with 10 µg/ml OVA or rHA in
the presence of 4 µg/ml anti-CD28 antibodies (37.51) overnight. Cells were har-
vested and stained with ﬂuorescence-conjugated H-2Kb-restricted OVA257–264
(SIINFEKL) tetramer (NIH tetramer core facility), anti-CD4 (GK1.5), and anti-
CD8 antibodies (53–6.7). For intracellular cytokine staining, Brefeldin A (420601,
Biolegend) was added 5 h before cell harvest. PBMCs were then stained with
ﬂuorescence-conjugated anti-CD4 and anti-CD8 antibodies, ﬁxed and permeabi-
lized, and then stained with ﬂuorescence-conjugated anti-IFNγ (XMG1.2) and
anti-IL4 antibodies (11B11). To detect OVA-speciﬁc CD4+ and CD8+ T cells in
splenocytes, single-cell suspensions were prepared by passing spleen through 40 µm
cell strainers. After RBC lysis, splenocytes were stimulated with 10 µg/ml OVA in
the presence of anti-CD28 antibodies overnight. Brefeldin A was added 5 h before
cell harvest. Splenocytes were similarly stained with ﬂuorescence-conjugated anti-
CD4, CD8, IFNγ, and IL4 antibodies. Cells were then subjected to ﬂow cytometry
analysis in BD FACSVerse.
Tumor model. E.G7-OVA cells (CRL-2113, ATCC) were cultured in PRMI 1640
media supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and 100 U/
ml penicillin and 100 µg/ml streptomycin. Cells were harvested at ~ 80% con-
ﬂuency, washed in PBS, and 5 × 105 or 1 × 106 cells were subcutaneously injected
into right ﬂank of C57BL/6 mice. Tumor size was measured with a digital caliper
and tumor volume was calculated with the following formula: v ¼ 12 ab2, where a
and b are long and short diameter of the tumor, respectively.
HAI titer. Serum HAI titer was measured following a well-established protocol45.
In brief, serum samples were incubated with receptor-destroying enzyme II
and then heat inactivated to remove complement activities. Serum samples
were further adsorbed with chicken RBCs to remove non-speciﬁc binding. Serum
samples were subjected to a twofold serial dilution and incubated with four
hemagglutinating units of pdm09 viruses (A/California/07/2009). Pdm09
viruses were obtained from IRR (FR-201) and propagated in 9–11-day embryonic
eggs for use in this study. Chicken RBCs were added and HAI titer was determined
as the reciprocal of the highest dilution that completely inhibited agglutination
of chicken RBCs.
Mouse adaptation of pdm09 viruses. Pdm09 viruses were adapted in C57BL/6
mice for use in challenge studies45. In brief, mice were infected by intranasal
instillation of 20 μl inﬂuenza viruses at ~ 105 50% tissue culture infective dose
(TCID50). Lung was aseptically harvested 3 days later and lung homogenates were
used as inoculum for the next passage. Adaptation was repeated four times and
viral titer of the last lung homogenates was measured by TCID50 assay45. In brief,
inﬂuenza viruses were subjected to a 10-fold serial dilution and then incubated with
Madin–Darby Canine Kidney cells (CCL34, ATCC) for 4 days. Chicken RBCs were
added and agglutination pattern was recorded. TCID50 was calculated based on the
formula provided in the protocol45.
Lethal viral challenge. LD50 of mouse-adapted viruses was ﬁrst determined45. In
brief, six groups of mice (n= 4) were infected with 100, 101, 102, 103, 104, and 105
TCID50 inﬂuenza viruses. Survival and body weight were monitored daily for
14 days. LD50 was calculated by the method of Reed and Muench45. For lethal
viral challenge, mice were intranasally inoculated with 10 × LD50 of inﬂuenza
viruses under light anesthesia. Body weight and survival were monitored daily for
14 days. Mice with body weight loss more than 25% were euthanized and regarded
as dead.
Antigen uptake and maturation. Mice were exposed to RF or sham treatment
followed by ID injection of 2 µg AF647-OVA into RF or sham-treated skin. Skin
was dissected 18 h later and single-cell suspensions were prepared by digestion in
collagenase D and dispase followed by staining with ﬂuorescence-conjugated anti-
CD11c (N418), CD40 (1C10), CD80 (16–10A1), and CD86 (GL-1). Cells were
subjected to ﬂow cytometry analysis of percentage of AF647+CD11c+ cells and
also MFI of CD40, CD80, and CD86 within AF647+CD11c+ cells. For DC subset
analysis in skin and dLNs, skin and LN cells were stained with ﬂuorescence-
conjugated anti-CD11c (N418), MHC II (M5/114.15.2), Langerin (4C7), CD11b
(M1/70), CD103 (2E7), CD8α (53–6.7), and CD80 (16–10A1). Cells were then
subjected to ﬂow cytometry analysis of percentage of AF647+ cells as well as MFI
of CD80 in different DC subsets in skin and dLNs as reported18,27,28.
Adoptive transfer of OT-I T cells. LNs and spleens were harvested from OT-I
transgenic mice (003831, Jackson Laboratories), in which CD8+ T cells recognize
OVA residues 257–264 in the context of H-2Kb. LNs and spleens were passed
through 40 µm cell strainers to prepare single-cell suspensions. After RBC lysis,
cells were subjected to magnetic beads-based negative puriﬁcation of naïve CD8+
T cells with a commercial kit (130–096–543, Miltenyi Biotech). CD8+ T cells from
OT-I mice (designated as OT-I cells) were then stained with 5 µM CFSE (C34554,
Thermo Fisher Scientiﬁc) at 37 ˚C for 20 min. OT-I cells were thoroughly washed
in PBS and then adjusted to 107 cells/ml in PBS. OT-I cells (106) were then
intravenously injected into C57BL/6 mice via lateral tail vein. OVA immunization
was conducted 24 h later.
Western blotting. Skin was homogenized in T-PER™ Tissue Protein Extraction
Reagent (78510, Thermo Fisher Scientiﬁc). Total protein levels were quantiﬁed by
BCA protein assay kit (23227, Thermo Fisher Scientiﬁc). Samples that contained
the same amount of proteins were subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) separation. Proteins were then
transferred to a polyvinylidene diﬂuoride (PVDF) membrane and blocked
with 5% non-fat milk at 4˚C overnight. PVDF membrane was then incubated
with rabbit anti-HSP70 antibodies (1:2000, AF1663, R&D Systems) (no cross-
reactivity with HSc70) at room temperature for 90 min. After washing in Tris-
buffered saline (TBS) containing 0.05% Tween 20 (TBST), PVDF membrane was
incubated with HRP-conjugated anti-rabbit secondary antibodies (1:2000, 7074P2,
Cell Signaling Technology) at room temperature for 1 h. After washing in TBST,
PVDF membrane was incubated with Pierce ECL Western Blotting Substrate
(32109, Thermo Fisher Scientiﬁc). PVDF membrane was imaged under myECL
Imager (Thermo Fisher Scientiﬁc). PVDF membrane was stripped in stripping
buffer (62 mM Tris-HCl, pH 6.8, 2% SDS, 100 mM β-mercaptoethanol) for
immune blotting detection of other proteins. In brief, stripped PVDF membrane
was blocked, incubated with anti-GAPDH antibodies (1:2000, 5174 s, Cell Signaling
Technology), rabbit anti-HSc70 polyclonal antibodies (1:500, AB1427, Abcam)
(no cross-reactivity with HSP70), or rabbit anti-HSP90 polyclonal antibodies
(1:1000, PA3013, Thermo Fisher Scientiﬁc) followed by the same procedures for
detection of GAPDH, HSc70, and inducible HSP90 expression. Complete stripping
was veriﬁed by negative signals obtained from incubation of stripped PVDF
membrane with substrates alone or sequential incubation with secondary anti-
bodies and substrates.
Histology and IHC analysis. Mice were exposed to RF or sham treatment.
Skin was dissected at indicated times, ﬁxed in formalin, and then subjected to
parafﬁn sectioning. Parafﬁn sections were subjected to standard hematoxylin
and eosin staining to visualize microscopic structures or Trichrome staining to
visualize dermal collagen levels. For IHC, parafﬁn sections were deparafﬁnized
and then subjected to heat-induced epitope retrieval with antigen unmasking
solution (H-3300, Vector Laboratories). Endogenous peroxidase was depleted
with 0.3% hydrogen peroxide. Tissue sections were then incubated with SuperBlock
(Thermo Fisher Scientiﬁc) and then rabbit anti-mouse polyclonal HSP70 anti-
bodies (1:100, AF1663, R&D Systems) at 4 ˚C overnight. Tissue sections were
then rinsed in TBS for three times followed by incubation with HRP-conjugated
anti-rabbit secondary antibodies (K4063, DAKO). After washing in TBS, DAB
substrate was added and reaction was stopped 2 min later. Sections were coun-
terstained with 20% Gill III hematoxylin, dehydrated, and then cover slipped.
Images were taken under Nikon Eclipse E600 microscope by an investigator
unknown of sample groups.
Real-time PCR analysis. Adjuvant-treated skin was dissected at indicated times.
Total RNA was isolated with Trizol method and reverse transcribed. Relative gene
expression of cytokines and chemokines was analyzed by real-time PCR in Applied
Biosystems ViiA 7 using GAPDH as internal control. PCR primers of each gene
refer to Supplementary Table 1.
Immune cell recruitment. Skin was digested in 0.2% collagenase D (Roche
Diagnostics, Mannheim, Germany) and 0.6U/ml dispase (Gibco, Invitrogen,
Carlsbad, CA) in PBS at 37˚C for 3 h with intermittent vortexing. Single-cell
suspensions were then passed through 40 µm cell strainer and stained with
ﬂuorescence-conjugated antibodies against Ly6C (HK1.4), CD11b (M1/70), CD11c
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(N418), MHC class II (m5/114.15.2), Ly6G (1A8), F4/80 (BM8) to identify neu-
trophils (CD11b+, Ly6Ghi, Ly6C+, F4/80-), eosinophils (CD11b+, Ly6Gint, Ly6C−,
F4/80int), monocytes (CD11b+, Ly6G−, Ly6C+, F4/80int), macrophages (CD11b+,
F4/80hi), and mDCs (CD11b+, CD11c+, MHC II+) as reported46. The gating
strategy was shown in Supplementary Figure 2 together with gating strategies in
other experiments.
Statistics. Values were expressed as mean ± SEM. Student’s t-test was used to
analyze difference between two groups and one-way analysis of variance (ANOVA)
with Tukey’s multiple comparison test was used to compare differences for
more than two groups, except otherwise speciﬁed. Two-way ANOVA with
Bonferroni post test was used to compare differences of tumor growth at different
time points between groups. Log-rank (Mantel–Cox) test with Bonferroni cor-
rection was used to compare differences of survival between groups. P-value
was calculated by PRISM software (GraphPad, San Diego, CA) and considered
signiﬁcant if it was < 0.05.
Data availability
The data that support the ﬁndings of this study are available from the corresponding
author upon request.
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